Abstract
Chronic fibrotic liver diseases such as viral hepatitis eventually develop liver cirrhosis, which causes occurrence of hepatocellular carcinoma (HCC). Given the limited therapeutic efficacy in advanced HCC, prevention of HCC development could be an effective strategy for improving patient prognosis. However, there is still no established therapy to meet the goal. Studies have elucidated a wide variety of molecular mechanisms and signaling pathways involved in HCC development. Genetically-engineered or chemically-treated experimental models of cirrhosis and HCC have been developed and shown their potential value in investigating molecular therapeutic targets and diagnostic biomarkers for HCC prevention. In this review, we overview potential targets of prevention and currently available experimental models, and discuss strategies to translate the findings into clinical practice.
Keywords: Animal model, chemoprevention, clinical trial, hepatocellular carcinoma, liver cirrhosis, prevention, bile duct ligation, carbon tetrachloride, connective tissue growth factor, direct acting antiviral, diethylnitrosamine, dimethylnitrosamine, extracellular matrix, epidermal growth factor, genetic hemochromatosis
Current Cancer Drug Targets
Title:Prevention of Hepatocellular Carcinoma: Potential Targets, Experimental Models, and Clinical Challenges
Volume: 12 Issue: 9
Author(s): Yujin Hoshida, Bryan C. Fuchs and Kenneth K. Tanabe
Affiliation:
Keywords: Animal model, chemoprevention, clinical trial, hepatocellular carcinoma, liver cirrhosis, prevention, bile duct ligation, carbon tetrachloride, connective tissue growth factor, direct acting antiviral, diethylnitrosamine, dimethylnitrosamine, extracellular matrix, epidermal growth factor, genetic hemochromatosis
Abstract: Chronic fibrotic liver diseases such as viral hepatitis eventually develop liver cirrhosis, which causes occurrence of hepatocellular carcinoma (HCC). Given the limited therapeutic efficacy in advanced HCC, prevention of HCC development could be an effective strategy for improving patient prognosis. However, there is still no established therapy to meet the goal. Studies have elucidated a wide variety of molecular mechanisms and signaling pathways involved in HCC development. Genetically-engineered or chemically-treated experimental models of cirrhosis and HCC have been developed and shown their potential value in investigating molecular therapeutic targets and diagnostic biomarkers for HCC prevention. In this review, we overview potential targets of prevention and currently available experimental models, and discuss strategies to translate the findings into clinical practice.
Export Options
About this article
Cite this article as:
Hoshida Yujin, C. Fuchs Bryan and K. Tanabe Kenneth, Prevention of Hepatocellular Carcinoma: Potential Targets, Experimental Models, and Clinical Challenges, Current Cancer Drug Targets 2012; 12 (9) . https://dx.doi.org/10.2174/15680096112091129
DOI https://dx.doi.org/10.2174/15680096112091129 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Beneficial Effects of Garlic in Oncohematology
Mini-Reviews in Medicinal Chemistry Cancer Immunoinformatics: A Promising Era in the Development of Peptide Vaccines for Human Papillomavirus-induced Cervical Cancer
Current Pharmaceutical Design Withdrawal Notice: The Prognostic Value of Prognostic Biomarkers in Esophageal Squamous Cell Carcinoma in Iranian Population
Current Cancer Therapy Reviews Overview of Genomic Insights into Chicken Growth Traits Based on Genome- Wide Association Study and microRNA Regulation
Current Genomics Molecular and Thermodynamic Studies on DNA Triplex Formed in the Promoter Region of HMGB1 Gene as a Selective Target for Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Apoptosis at the Interface of Immunosuppressive and Anticancer Activities: The Examples of Two Classes of Chemical Inducers, Oxysterols and Alkylating Agents
Current Medicinal Chemistry Peptides as Tight Junction Modulators
Current Pharmaceutical Design Statin-Induced Myotoxicity: Pharmacokinetic Differences among Statins and the Risk of Rhabdomyolysis, with Particular Reference to Pitavastatin
Current Vascular Pharmacology Microbicides for Prevention of Transmission of Sexually Transmitted Diseases
Current Pharmaceutical Design The Role of Cannabinoids in Inflammatory Modulation of Allergic Respiratory Disorders, Inflammatory Pain and Ischemic Stroke
Current Drug Targets Development of Topical Nanocarriers for Skin Cancer Treatment Using Quality by Design Approach
Current Medicinal Chemistry Searching for the Magic Bullet: Anticancer Platinum Drugs Which Can Be Accumulated or Activated in the Tumor Tissue
Anti-Cancer Agents in Medicinal Chemistry Antioxidants in the Practice of Medicine; What Should the Clinician Know?
Cardiovascular & Hematological Disorders-Drug Targets Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment
Clinical Cancer Drugs Schistosoma mansoni Changes the Activity of Phase II Drug-Metabolizing Enzymes: Role of Praziquantel as Antibilharzial Drug
Drug Metabolism Letters Design, Synthesis, and Biological Evaluation of Novel Thiazolyl Substituted Bis-pyrazole Oxime Derivatives with Potent Antitumor Activities by Selectively Inducing Apoptosis and ROS in Cancer Cells
Medicinal Chemistry Natural Bioactive Compounds and Biotechnological Potential of Marine Bacteria
Current Pharmaceutical Biotechnology The Application of Fungal Beta-glucans for the Treatment of Colon Cancer
Anti-Cancer Agents in Medicinal Chemistry A Therapeutic Potential of Animal β-hairpin Antimicrobial Peptides
Current Medicinal Chemistry Increased Expression of IRE1α Associates with the Resistant Mechanism of Osimertinib (AZD9291)-resistant non-small Cell Lung Cancer HCC827/OSIR Cells
Anti-Cancer Agents in Medicinal Chemistry